Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.77
-0.7923-2.29%
Post-market: 34.000.2313+0.68%16:10 EDT
Volume:191
Turnover:7K
Market Cap:13.51M
PE:- -
High:34.00
Open:34.00
Low:33.77
Close:34.56
52wk High:34.98
52wk Low:26.88
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.11
T/O Rate:0.05%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Grindr to acquire Freddie for $250M in cash and stock

TIPRANKS
·
Yesterday

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Yesterday

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Yesterday

Gilead put volume heavy and directionally bearish

TIPRANKS
·
Yesterday

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Yesterday

Lilly's Closely Watched Obesity Combination Therapy Shows Greater Weight Loss in Mid-Stage Trial

Deep News
·
Yesterday

Verici Dx boosts Tutivia growth and expands transplant diagnostics footprint

TIPRANKS
·
Yesterday

Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says

MT Newswires Live
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Sep 30

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30